Market Overview

The Global Breast Cancer Therapy Market was valued at USD 66,545.6 million in 2023 and is expected to reach USD 124,086.6 million by 2031 while growing at a CAGR of 8.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global breast cancer therapy market growth. The selection of breast cancer therapy hinges primarily on factors like the cancer's type and stage, the patient's general health, and specific tumor characteristics such as hormone receptor status and HER2 status. The primary modalities of breast cancer therapy include Surgery, Radiation Therapy, Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Bone-directed Therapy.

Advancements in medical technology, including enhanced imaging methods and targeted drug delivery systems, coupled with the rising incidence of breast cancer and the implementation of awareness and screening programs, propel market growth. However, the high costs of treatment and the adverse effects associated with therapy act as impediments to market expansion.

Furthermore, the global breast cancer therapy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Therapy Analysis

The Global Breast Cancer Therapy Market is segmented among Targeted Therapy, Hormonal Therapy, Chemotherapy, and Immunotherapy, based on Therapy. In 2023, Targeted Therapy accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Breast Cancer Therapy Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd, Eli Lilly and Company, Genentech, GlaxoSmithKline PLC, Halozyme Inc., Novartis AG, Pfizer Inc., Hikma Pharmaceuticals, Baxter Healthcare Corporation, and FRESENIUS KABI.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Breast Cancer Therapy Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Breast Cancer Therapy Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Breast Cancer Therapy Market Segmentation, By Therapy

• Global Breast Cancer Therapy Market Share Analysis, By Therapy

• Global Breast Cancer Therapy Market Growth Analysis, By Therapy

• Global Breast Cancer Therapy Market Trends, By Therapy

o Targeted Therapy

o Hormonal Therapy

o Chemotherapy

o Immunotherapy

6. Global Breast Cancer Therapy Market Segmentation, By Region

• Global Breast Cancer Therapy Market Share Analysis, By Region

• Global Breast Cancer Therapy Market Growth Analysis, By Region

• Global Breast Cancer Therapy Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• AstraZeneca PLC.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Bristol-Myers Squibb Company

• Eisai Co. Ltd

• Eli Lilly and Company

• Genentech

• GlaxoSmithKline PLC

• Halozyme Inc.

• Novartis AG

• Pfizer Inc.

• Hikma Pharmaceuticals

• Baxter Healthcare Corporation

• FRESENIUS KABI

*Similar analysis will be provided for each company listed above.